MTHFR-Gene Polypmorphisms and its prognostic impact for response of radiochemotherapy in rectal cancer

MTHFR-Gene Polypmorphisms and its prognostic impact for response of radiochemotherapy in rectal cancer - MTHFR

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00022818

Enrollment

160

Registered

2020-08-11

Start date

2020-08-23

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C20

Interventions

Group 1: Genotyping MTHFR-Polymorphismen at SNP-Locus rs1801133 and rs1801131 will be done after operation of neoadjuvant treated rectal cancer. Those patinents with very good histopathological regres

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: histological verified rectal cancer within stage II-III // signed declaration of consent

Exclusion criteria

Exclusion criteria: patients without complience or patinents who are not able to travel for repetitive examinations to hospital // patients younger than 18 years // pregnant or brestfeeding mothers // secondary carcinomas // persons who are to be kept in an institution by judicial or official order

Design outcomes

Primary

Measure	Time frame
Primary outcome of the study is genotype at SNP rs1801133 and rs 1801131. All patients from arm 1 and 2 will be genotyped at this locus after operation. Genotyping will be done by pyrolysis sequencing.	—

Secondary

Measure	Time frame
1. tumor-free survival rate 2. overall survival	—

Countries

Germany

Contacts

Public ContactErnst W. Kolbe

Universitätsklinik für Allgemein- Viszeral- und Thoraxchirurgie, Proktologie

ernst-wolfgang.kolbe@klinikum-herford.de05221-942421

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026